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Entry of the bacterial pathogen Listeria monocytogenes into host
epithelial cells is critical for infection and virulence. One major
pathway for Listeria entry involves binding of the bacterial protein
Internalin B to the host receptor tyrosine kinase Met (hepatocyte
growth factor receptor). Activation of Met and downstream signaling cascades is critical for Listeria entry. Internalin B is composed
of several structural domains including an N-terminal leucine-rich
repeat that is sufficient for binding Met and stimulating downstream signal transduction. Internalin B is monomeric, whereas
the leucine-rich repeat is dimeric when expressed as an isolated
fragment. The different quaternary states of Internalin B and the
leucine-rich repeat suggest that these two Met ligands might cause
distinct biological effects. Here we demonstrate that Internalin B
and the leucine-rich repeat fragment exhibit agonist properties
that differentially influence Met down-regulation in lysosomes.
Specifically, Met stability is increased in response to the leucinerich repeat fragment compared with Internalin B. Interestingly,
Internalin B and the leucine-rich repeat stimulate equivalent rates
of clathrin-mediated Met internalization. However, the leucinerich repeat is defective in promoting lysosomal down-regulation of
Met and instead enhances receptor recycling to the cell surface. In
addition, the leucine-rich repeat causes prolonged Met activation
(phosphorylation) and increased cell motility compared with Internalin B. Taken together, our findings indicate that individual domains of
Internalin B differentially regulate Met trafficking. The ability of the
leucine-rich repeat fragment to promote Met recycling could account
for the increased cell motility induced by this ligand.

The Listeria monocytogenes surface protein Internalin B
(InlB)2 is a 630-amino acid protein critical for bacterial invasion

* This work was supported, in whole or in part, by National Institutes of Health
Grants CA-112605 and CA-119075 (to L. A. E.). This work was also supported by National Science Foundation Grant IBN-343739 (to L. A. E.) and
Canadian Institutes of Health Research Grant MT-15497 (to K. I.). The costs
of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
□
S
The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S6.
1
To whom correspondence should be addressed. Tel.: 409-772-2775; Fax:
409-747-1938; E-mail: laelferi@utmb.edu.
2
The abbreviations used are: InlB, Internalin B; LRR, leucine-rich repeat; CHC,
clathrin heavy chain; EEA1, early endosomal antigen; EGF, epidermal

774 JOURNAL OF BIOLOGICAL CHEMISTRY

into a broad range of host cells including endothelial cells,
hepatocytes, and epithelial cell lines such as Vero and HeLa
cells (1– 4). In addition to the bacterial-bound form, soluble
InlB is detected in bacterial supernatants (5, 6) and is active in
promoting Vero cell infection by a Listeria mutant lacking InlB
(7). The host receptor for InlB is Met, a receptor tyrosine kinase
for the endogenous ligand hepatocyte growth factor (HGF)
(8). Tight regulation of Met signaling elicits multiple cellular
responses critical for mammalian development including
proper cellular growth, survival, and migration (for review, see
Ref. 9). In adult tissues, Met signaling is intrinsic for organ
homeostasis and tissue remodeling (10 –12).
InlB shares many of the agonist activities of HGF including
increased cell proliferation, epithelial cell motility, and membrane ruffling (5, 8, 13). Recent structural studies show that
HGF and InlB directly bind to discrete sites on the extracellular,
sema domain of Met (14 –16), consistent with early biochemical studies showing that InlB and HGF do not compete for
receptor occupancy (8, 14). Despite these differences, HGF and
InlB activate similar signaling cascades downstream of Met
autophosphorylation including pathways involving Grb2,
Gab1, phosphatidylinositol 3-kinase and MAP kinase (MAPK)
(2, 5, 7, 17, 18). We previously reported that like HGF, InlB
induces Met endocytosis in a process requiring clathrin-heavy
chain, the clathrin adaptor epidermal growth factor phosphorylation substrate 15 (Eps15), Grb2, and the E3 ubiquitin ligase
Cbl (18, 19). After internalization, InlB- and HGF-activated
Met are targeted for lysosomal degradation. Met degradation is
dependent on phosphatidylinositol 3-kinase activity and hepatocyte receptor substrate (Hrs) (18), a protein that interacts
with ubiquitinated cargo and is important for endosomal sorting (20 –23).
InlB is a modular protein consisting of a N-terminal cap followed by a 213-amino acid leucine-rich repeat (LRR), an interrepeat domain, and a C-terminal region containing “GW” modules that anchor InlB non-covalently to the bacterial cell wall
(24, 25). InlB binds Met in a 1:1 stoichiometry primarily
growth factor; HGF, hepatocyte growth factor; Met, hepatocyte growth
factor receptor; LRR, leucine-rich repeat; MVB, multivesicular body; Tfn,
transferrin; ANOVA, analysis of variance; MDCK, Madin-Darby canine kidney; WT, wild type; PBS, phosphate-buffered saline; FACS, fluorescenceactivated cell sorter; siRNA, small Interfering RNA.
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through the concave surface of the LRR region, although a second contact involving the inter-repeat region of InlB strengthens this interaction (14). Biochemical studies confirm that a
fragment containing only the N-cap and LRR domains (i.e. the
LRR fragment) comprises the minimal region for binding and
inducing Met phosphorylation (7, 8).
Surprisingly, the LRR fragment used in studies on Met activation (7, 17) has a different quaternary structure than InlB.
Whereas full-length InlB is monomeric, the isolated LRR
domain is a disulfide-linked dimer. LRR dimerization results
from a cysteine residue in InlB that is normally unavailable for
disulfide formation. Truncation of InlB to generate the LRR
fragment results in the surface exposure of this cysteine residue
located near the C terminus of the LRR fragment. The different
quaternary structures of monomeric InlB and the dimeric LRR
fragment raise the possibility that these two Met ligands could
exhibit some differences in biological activity.
Although it is unclear whether the LRR fragment is produced
physiologically during Listeria infection, we are interested in
using InlB and its derivatives as tools to examine aspects of
Met-mediated signal transduction and trafficking. Our structure/function analysis of InlB identified the LRR fragment with
agonist properties reminiscent of InlB, with the exception that
LRR promotes Met stability. Down-regulation plays a key role
in regulating the temporal activity of signaling receptors, and
mutations or other conditions that interfere with down-regulation are thought to contribute to the development of several
cancers (26, 27). “Down-regulation” refers to ligand-induced
depletion of a surface receptor, typically resulting from receptor internalization and degradation in a lysosomal compartment (28). We found that compared with InlB, the LRR fragment is defective in promoting Met down-regulation. LRR and
InlB induce Met internalization at similar rates, indicating that
the differences in receptor degradation caused by these two
ligands are due to alterations in intracellular trafficking. Compared with InlB, the LRR fragment is defective in targeting Met
to the degradative pathway and, instead, promotes receptor
recycling to the plasma membrane. InlB and LRR are comparable in their abilities to induce initial Met activation (i.e. Met
tyrosine phosphorylation); however, receptor phosphorylation
in response to the LRR fragment is more sustained than that
induced by InlB. The ability of LRR to prolong Met phosphorylation raised the possibility that the truncated ligand might be
more potent than InlB for inducing one or more Met-mediated
biological activities. Consistent with this idea, we show that the
LRR fragment was more effective than InlB in promoting epithelial cell motility. Collectively, our results indicate that individual domains of InlB differentially regulate Met trafficking
and impact Met-mediated biological activity.

EXPERIMENTAL PROCEDURES
Reagents, Antibodies, and Plasmids—All general reagents
were obtained from Fisher or Sigma-Aldrich unless indicated
otherwise. The following antibodies were purchased as indicated: transferrin receptor (Invitrogen), anti-actin (Sigma-Aldrich), anti-human HGF receptor (R & D Systems Inc., Minneapolis, MN), clathrin heavy chain (CHC), caveolin, EEA1 (BD
Biosciences), Met C-12, and Met C-28 (Santa Cruz BiotechnolJANUARY 9, 2009 • VOLUME 284 • NUMBER 2

ogies Inc, Santa Cruz, CA), phospho-Met Tyr-1234, Tyr-1235
(Upstate Biotechnology, Billerica, MA), phospho-Met Tyr1003 (ABR-Affinity BioReagents, Golden, CO), peroxidaseconjugated goat anti-mouse immunoglobulin G (IgG), and goat
anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA). Plasmids encoding N-terminal His-tagged
LRR or LRR-C242A construct in pET28a were kindly provided
by Dr. Partho Ghosh (University of California, San Diego, CA)
and have been described elsewhere (17, 18, 25). Recombinant
human HGF was purchased from PeproTech Inc, Rocky Hill,
NJ, and Alexa594-labeled-transferrin (Tfn) and Alexa594-labeled dextran was obtained from Invitrogen.
Cell Line and Cell Culture—Human cervical epithelial adenocarcinoma (HeLa) and Madin-Darby canine kidney (MDCK)
cells were grown in complete media (Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum and
1⫻ penicillin/streptomycin) at 37 °C with 5% CO2. The H10 cell
line derived from kidney epithelial cells from embryos of Met
null ⫺/⫺ mice (29) was kindly provided by Dr. Lloyd Cantley
(Yale University School of Medicine). H10 derivatives stably
expressing wild type (WT) or mutant Met alleles (KinD) (19)
were grown in the Dulbecco’s modified Eagle’s medium/F-12
(1:1) media supplemented with 10% fetal bovine serum, 5 g/ml
puromycin at 37 °C with 5% CO2. Cells were routinely starved
in media lacking sera (incomplete media) overnight at 37 °C
before use unless specified otherwise. For studies using
cycloheximide, cells were pretreated with 10 g/ml cycloheximide at 37 °C for 30 – 60 min to prevent de novo synthesis of Met during receptor stimulation as indicated in the
appropriate figure legends.
Ligand Purification and Labeling, Confocal Microscopy—
The purification and labeling of InlB and its derivatives has
been described in detail elsewhere (18). Gel filtration chromatography was used to separate dimeric LRR from LRR monomers. Briefly, 2–2.5 mg of LRR in 120 l was injected (10
l/run) onto a Superdex 75 (GE Healthcare) gel filtration column at a flow rate of 1 ml/min in 500 mM NaCl, 50 mM HEPES,
pH 7.4, and the separation of LRR dimers from monomers was
monitored by size and SDS/PAGE. For confocal microscopy,
serum-starved cells grown on coverslips were co incubated in
incomplete media containing 5.0 g/ml Alexa594-labeled Tfn
or 5.0 g/ml Alexa594-labeled dextran with 2 nM Alexa488-labeled InlB or 2 or 10 nM Alexa488-labeled LRR or LRR-C242A.
The cells were rapidly cooled and analyzed for ligand uptake as
previously published (18, 19). All images were taken using identical acquisition parameters, and the amount of internalized
LRR or LRR-C242A is expressed as a percentage of internalized
InlB. Colocalization analyses were preformed as previously
described (30) on cells stained for endogenous EEA1 or CD63.
Routinely, a minimum of 10 cell areas was analyzed using MetaMorph software v7.1.3.0 (Molecular Devices, Union City, CA),
and the data were normalized to the percentage of co-localization with EEA1 at the 0-min chase time.
Flow Cytometry-based Recycling Assay—Serum-starved
HeLa cells grown on 10-cm plates were incubated with 10
g/ml cycloheximide for 1 h at 37 °C to inhibit protein synthesis. The cells were then stimulated with 2 nM InlB or 10 nM LRR
for 15 min at 37 °C to induce Met internalization. Residual surJOURNAL OF BIOLOGICAL CHEMISTRY
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face Met was cleaved by incubation with 0.25% trypsin (Invitrogen) for 30 min on ice. Cells were collected by centrifugation
and washed in PBS containing 2% fetal bovine serum (FACS
buffer) before resuspension in serum-free media containing 10
g/ml cycloheximide. Cells were incubated at 37 °C for 0, 5, 10,
or 15 min to allow Met trafficking. After the appropriate chase
time cells were shifted to ice to prevent further endocytic trafficking of Met and were resuspended to a concentration of 1 ⫻
107 cells/ml in FACS buffer. To determine the level of Met present on the cell surface, 2 ⫻ 105 cells were aliquoted into triplicate wells of a 96-well plate. Cells were incubated with 10 g/ml
goat anti-HGF receptor antibody for 30 min on ice followed by
20 min of incubation with donkey anti-goat phycoerythrinconjugated secondary antibody. After staining, cells were fixed
with 2% formaldehyde (Ted Pella Inc., Redding, CA) in FACS
buffer for 20 min at room temperature. Residual formaldehyde
was removed by washing in FACS buffer before measurement
of the mean yellow fluorescent signal for 20,000 events by a BD
FACSArray. Experiments were performed in triplicate, and the
values were expressed as the level of Met present on the cell
surface after each chase time. Data were normalized to the level
of Met present on the cell surface after 0 min of chase, so that
the surface level of Met at time 0 was 1.
Small Interfering RNA (siRNA) Transfection Studies—siRNA
depletion experiments were performed using commercially
available control, Grb2, and Met (Dharmacon, Chicago, IL)
or CHC (Santa Cruz Biotechnologies Inc., Santa Cruz, CA)
siRNAs. Cells were cultured for 1 day before transfection and
transfected using empirically determined concentrations of
siRNA using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s specifications. Typically cells were
treated with 40 – 60 pmol of siRNA with 1–1.5 l of Lipofectamine 2000, respectively, to routinely accomplish a 95%
decrease in protein levels as determined by Western analysis.
All experiments were routinely performed 72 h after siRNA
transfection.
Cell Surface Enzyme-linked Immunosorbent Assay—Duplicate sets of HeLa cells were plated in 4-well tissue culture plates
(Nunc A/S, Rochester, NY) at a concentration of 2 ⫻ 105/well.
The following day sera-starved cells were stimulated with 2 nM
InlB, 2 nM LRR, 10 nM LRR, or 2 nM LRR-C242A in incomplete
media for 2– 8 min at 37 °C. The cells were rapidly cooled on ice
to inhibit endocytosis, washed three times with ice-cold PBS,
and then fixed with 4% formaldehyde (Ted Pella Inc., Redding,
CA) in PBS for 10 min at room temperature. The cells were
incubated with primary anti-human HGF receptor antibody in
PBS containing 10% horse serum for 1 h at room temperature,
and unbound antibody was removed using three ice-cold PBS
washes, then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody. For measuring total
receptor, one duplicate plate of cells was first fixed in paraformaldehyde and then permeabilized with 0.2% Triton X-100 for 5
min before the addition of the primary antibody. One well of
cells lacking primary antibody was used as an additional negative control. To detect antibody-bound protein complexes, cells
were incubated with 1-Step-ABTS reagent (Thermo Scientific,
Rockford, IL) for 30 min at room temperature, and the colorimetric reaction was terminated by the addition of 1% SDS. The
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absorbance at 405 nm was measured using a VERSAmax microplate reader and SOFTmax威 PRO 3.0 software (Molecular
Devices, Sunnyvale, CA). Experiments were performed in triplicate, and values were calculated as the ratio of surface Met (X)
to total receptor (Y) at each time point (tx), normalized to the
control value at time zero (t0). For the kinetic studies, values
representing the relative amount of internalized Met were calculated using the formula ((X/Y)t0 ⫺ (X/Y)tx)/tx.
Western Blot Analysis—Western analysis was performed
using ECL plus (GE Healthcare), and the resulting digitized
blots were quantified using MetaMorph software as previously
described (19).
Wound Healing and Three-dimensional Tubulogenesis
Assays—Cell migration was analyzed using an in vitro woundhealing model (31). Briefly, confluent monolayers of MDCK or
HeLa cells were cultured in 6-well plates and serum-starved for
48 or 24 h, respectively, in media supplemented with 0.2% fetal
bovine serum before each experiment. MDCK cells were
wounded mechanically by scraping with a 200-l pipette tip (3
separate wounds per well). Immediately after wounding, the
cells were incubated in media containing ligand. At the indicated time points after wounding, wound areas were imaged
with a NIKON TE2000 multifunction inverted microscope.
Multiple positioning marks were made to ensure that identical
areas were imaged between time points. The relative gap distance from three independent experiments was measured in
pixels using MetaMorph software. MDCK tubulogenesis assays
were performed in three-dimensional matrix gels as previously
described (32). Briefly, MDCK cells were trypsinized and suspended at 3 ⫻ 104 cells/ml in a neutralized rat tail collagen type
I (BD Biosciences) solution composed of 3.5 mg/ml glutamine,
2.35 mg/ml NaHCO3, 1⫻ minimum Eagle’s medium, 20 mM
Hepes (pH 7.6), and 2 mg/ml collagen I. 150 l of the cellcollagen I mixture was added to each well of 8-well culture
slides. After the collagen gel solidified, the cells were incubated
in complete media, which was changed every other day. Cysts
routinely formed at 7– 8 days under these conditions. For
inducing tubulogenesis, cysts were incubated in complete
media containing 2 nM InlB, 2 nM HGF, or 10 nM LRR and
renewed every 24 h. One group of cells incubated in growth
media lacking ligand served as a control. Phase contrast imaging was preformed using a NIKON TE2000 multifunction
inverted microscope equipped with a 20⫻ objective.

RESULTS
The LRR Fragment Is Unable to Target Met to the Degradative
Pathway—We previously reported using InlB as a tool to
understand the molecular mechanisms of Met endocytosis and
intracellular trafficking (18, 19). In particular, we were interested in identifying the minimal region of InlB required for Met
internalization and degradation. We focused on the LRR fragment of InlB (herein referred to as LRR) as it has been shown to
bind Met, induce receptor tyrosine phosphorylation, and activate downstream signaling cascades (7, 8, 33). InlB and LRR
were expressed and purified as recombinant His-tagged proteins and used to examine Met endocytosis and degradation.
Non-reducing SDS-PAGE shows that, consistent with earlier
reports (7, 8), InlB purifies as a monomeric species, whereas
VOLUME 284 • NUMBER 2 • JANUARY 9, 2009
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LRR is composed of monomers and disulfide-linked dimers
when purified under non-reducing conditions (supplemental
Fig S1A). LRR dimers convert to inactive monomers in the presence of reducing agents. Conversely, an LRR mutant incapable
of forming disulfide-linked homodimers due to a mutation in
the sole cysteine residue in LRR (C242A) purifies as a monomeric species under non-reducing conditions (supplemental
Fig S1A). To confirm that LRR dimers but not LRR monomers
are functionally active, the LRR preparation was subjected to
sizing chromatography. Fractions enriched in LRR monomers
or dimers were isolated, and their ability to induce Met phosphorylation at tyrosine 1234 and 1235 in the Met kinase domain
was examined. For these studies we used HeLa cells, an established cell model for examining the mechanisms for receptor
endocytosis and degradation. HeLa cells express high levels of
Met on their surface and have a well documented response to
Met signaling (34 –36). Western analysis using site-specific
phosphotyrosine antibodies confirmed tyrosine phosphorylation at positions 1234 and 1235 in response to dimeric LRR
(supplemental Fig. S1, B and C). Met activation was not
detected in response to monomeric LRR or the mutant LRRC242A, consistent with a previous study (7).
We next examined the fate of internalized Met in response to
InlB or LRR treatment. Two different LRR concentrations (2 or
10 nM) were used, as discrepancies in the level of Met activation
by LRR have been reported (7, 8, 14) possibly due to differences
in ligand preparations. HeLa cells pretreated with 10 g/ml
cycloheximide (30 min) were incubated in media lacking ligand
or with LRR or InlB for 10, 30, 60, or 120 min in the continued
presence of cycloheximide (Fig. 1, A and B). Cycloheximide was
included to prevent new protein synthesis that would otherwise
contribute to an underestimation of Met degradation. The level
of Met and activated receptor (as assessed by tyrosine phosphorylation of residues 1234 and 1235) decreased in response to
InlB over the time course of the experiment (Fig. 1B). Quantification of the Western bands revealed that levels of Met and
phospho-Met 60 –120 min after treatment with InlB were negligible, consistent with ligand-induced receptor internalization
and degradation. The apparent increase in Met levels at 5 min
was not observed in repeats of the experiment and is not statistically significant. Interestingly, treatment with 10 nM LRR, and
to a lesser extent, 2 nM LRR caused a delay in Met degradation.
Whereas total Met was reduced to 32.6% that of its original
levels in cells treated with InlB at 60 min, the steady state levels
of Met in response to 2 nM LRR and 10 nM LRR only decreased
to 64.8 and 86.8% that of starting levels, respectively (Fig. 1C).
These results indicate that LRR is less effective than InlB in
promoting Met degradation. In addition, Met phosphorylation
at tyrosine 1234 and 1235 was sustained up to 120 min in cells
treated with LRR, whereas phospho-Met was undetectable after
30 min in response to full-length InlB (Fig. 1). Hence, the
decrease in Met degradation observed in response to LRR correlates with prolonged Met activation.
The LRR Fragment and InlB Induce Comparable Met
Activation—We previously reported that Met kinase activity
was required for receptor endocytosis and, hence, degradation
in response to InlB (19). The differences we observed in LRRversus InlB-induced Met degradation could be the result of
JANUARY 9, 2009 • VOLUME 284 • NUMBER 2

FIGURE 1. Met degradation is delayed in response to LRR. A, structures of
full-length InlB and its N-terminal LRR fragment and the mutant C242A. Numbers represent amino acids. B, HeLa cells were incubated in medium containing 10 g/ml of cycloheximide (37 °C/30 min) before stimulation with cycloheximide-containing media supplemented with 2 nM InlB, 2 nM LRR, 10 nM
LRR, or medium lacking ligand (0 min) for the indicated times. The resulting
cell lysates were examined by Western analysis for total Met (Met), phosphorylated Met (p-Met, Y1234, Y1235), and actin. C, mean Met protein levels ⫾ S.E.
were quantified using MetaMorph software, and Met band density was normalized to actin density in the corresponding lane. Representative data are
shown for 2–3 separate experiments.

compromised Met activation. Therefore, we examined Met
phosphorylation (i.e. activation) over a range of ligand concentrations. Western analysis of lysates prepared from HeLa cells
treated with 2 nM InlB using site-specific phosphotyrosine antibodies detected Met phosphorylation at tyrosine 1003, 1234,
and 1235 (Fig. 2, A and B). Conversely, a comparable level of
Met phosphorylation in response to the LRR fragment was
only observed in cells treated with higher concentrations (10
nM) of this ligand (Fig. 2, A and B). As expected, no Met
activation was detected in control cells stimulated with LRRC242A. Contrary to our results, a previous study reported a
500-fold difference in the potency of the LRR fragment for
activating Met (7). The explanation for this discrepancy
remains unclear but may reflect differences in ligand preparations and/or cells lines used in the respective studies.
Regardless, our results and those reported by Banerjee et al.
(7) indicate that, when used at comparable concentrations,
the LRR fragment is a less potent Met agonist than fulllength InlB.
LRR Induces Normal Met Internalization—InlB induces Met
endocytosis through clathrin-coated pits in a Grb2-dependent
manner (18, 19). The delay in Met degradation observed in
response to LRR could be the result of altered kinetics for Met
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 2. Met activation in response to the LRR fragment of InlB is dosedependent. A, HeLa cells were treated with medium containing InlB, LRR, the
mutant LRR-C242A, or lacking ligand (Con) as indicated for 5 min at 37 °C. The
resulting cell lysates were examined by Western analysis using antibodies for
total Met (Met), key phosphotyrosines in the cytosolic region of Met (Y1234,
Y1235, or Y1003), or actin. B, mean Met protein levels ⫾ S.E. were quantified
using MetaMorph software, and Met band density was normalized to actin
density in the corresponding lane. Representative data are shown for 2–3
separate experiments.

internalization and/or receptor endocytosis via a clathrin-independent route. The rate of Met internalization in response to
InlB and/or LRR was examined using a cell surface enzymelinked immunosorbent assay to quantify the loss of surface Met
(Fig. 3). Duplicate sets of HeLa cells were treated with media
containing InlB or LRR for increasing times at 37 °C. The cells
were then rapidly cooled, and the relative amount of immunoreactive receptor remaining on the cell surface of one set of
plates was measured using an antibody specific to the extracellular domain of Met. The second set of time-matched plates
was permeabilized and then incubated with anti-Met antibody
to measure the amount of total (cell surface plus intracellular)
receptor. The ratio of surface to total Met was plotted against
time as an indication of the relative amount of endocytosed
Met, and the specific internalization rate constant (Ke) for each
ligand was calculated as a linear regression coefficient (18). To
correlate the level of Met phosphorylation with the internalization rate, we used two different concentrations of LRR in these
studies, 2 and 10 nM LRR. As shown in Fig. 3A, treatment with 2
nM InlB caused rapid Met uptake from the cell surface (KeInlB ⫽
0.102 ⫾ 0.007/min), consistent with our previous studies using
T47D/Met cells (18). A similar rate of receptor Met endocytosis
was observed in HeLa cells treated with 10 nM LRR (KeLRR(10 nM) ⫽
0.112 ⫾ 0.004/min), conditions that induce comparable levels
of Met phosphorylation as 2 nM InlB. However, Met internalization was slower in response to 2 nM LRR (KeLRR(2 nm) ⫽
0.061 ⫾ 0.004/min), which induced lower levels of receptor
phosphorylation than the same concentration of full-length

778 JOURNAL OF BIOLOGICAL CHEMISTRY

FIGURE 3. LRR induces rapid internalization of Met. A, HeLa cells were
treated for 2, 4, and 8 min in medium with InlB, LRR, or without ligand (0 min)
at 37 °C. The cells were rapidly cooled to 4 °C, and the level of residual surface
Met was determined using a cell enzyme-linked immunosorbent assay for
Met. The ratio of surface to total Met was plotted against time as an indication
of the relative amount of internalized Met (see “Experimental Procedures”),
and the specific internalization rate constant (Ke) for each ligand was calculated as a linear regression coefficient ⫾ S.E. Data are representative of three
independent experiments. B, HeLa cells were incubated in media containing
Alexa488-labeled InlB, LRR, or LRR-C242A at 37 °C for 10 min and analyzed by
confocal microscopy. Representative images of endocytosed InlB, LRR (closed
arrows), and low levels of LRR-C242A (open arrows) are shown. Scale, 10 m.
C, the relative amount of endocytosed ligand was quantified using Metamorph, and the data are normalized with respect to internalized InlB ⫾ S.E.
from 2–3 experiments (*, p ⬍ 0.01 ANOVA).

VOLUME 284 • NUMBER 2 • JANUARY 9, 2009
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enzyme-linked
immunosorbent
assay (supplemental Fig. S2). As
expected, treatment with InlB and
LRR causes WT-Met endocytosis.
Conversely, higher cell surface levels of KinD-Met were detected at
each time point, indicating the need
for Met kinase activity in LRR-stimulated receptor endocytosis, consistent with our earlier studies using
InlB (19).
InlB and LRR Induce Clathrinmediated Met Endocytosis—We
used RNA interference to examine
whether Met internalization in
response to LRR is clathrin-mediated and Grb2-dependent. HeLa
cells were transfected with siRNAs
targeting CHC or Grb2 (Fig. 4).
Under these conditions, near complete depletion of CHC was achieved. As expected, levels of Met,
transferrin receptor, and EEA1,
markers for clathrin-mediated endocytosis and early endosomes,
respectively (37–39), and caveolin 1,
a component of caveolae that has
FIGURE 4. Internalization of Met in response to LRR is clathrin- and Grb2-dependent. A, left panel, lysates
from untransfected HeLa cells (Un) or cells transfected with control (Con) or CHC siRNA were examined by been implicated in cell motility,
Western analysis using antibodies for CHC, transferrin receptor, Met, EEA1, and caveolin. Right panel, duplicate lipid trafficking and epidermal
sets of control or CHC-depleted HeLa cells were co-treated for 10 min at 37 °C with Alexa594-Tfn and Alexa488growth factor (EGF) receptor sigInlB, or Alexa488-LRR, and the relative amount of internalized ligand was analyzed by confocal microscopy.
Values represent the mean fluorescence intensity ⫾S.E. from 2–3 experiments and are expressed as a percent- naling (38, 40 – 43) remained unafage of control values. B, left panel, Western analysis was performed as indicated to confirm siRNA-mediated fected by treatment with siRNA tardepletion of Grb2 in HeLa cells. Right Panel, the relative amounts of internalized Tfn, InlB, and LRR in a 10-min/
37 °C pulse in HeLa cells transfected with control (Con) or Grb2 siRNAs were quantified by confocal microscopy. geting CHC (Fig. 4A). We reasoned
The average values of 2–3 experiments are expressed as a percentage of control values ⫾ S.E. (*, p ⬍ 0.01, that if LRR promoted clathrin-indeANOVA).
pendent Met endocytosis, then
receptor uptake would not be
InlB. We confirmed our findings using confocal microscopy altered in cells depleted of endogenous CHC. To test this idea
(Fig. 3, B and C) with Alexa488-labeled LRR and Alexa488-la- CHC-depleted cells were co-incubated with Alexa594-transbeled InlB to quantify Met internalization. Serum-starved HeLa ferrin (Alexa-Tfn) and Alexa488-labeled InlB (Alexa-InlB) or
cells were incubated with Alexa488-labeled InlB (2 nM), Alexa488-labeled LRR (Alexa-LRR) for 10 min at 37 °C using
Alexa488-labeled LRR (2 nM or 10 nM), or Alexa488-labeled ligand concentrations that induce comparable levels of Met
mutant LRR-C242A (2 nM) for 10 min at 37 °C. Under these phosphorylation. Ligand uptake was measured using confocal
conditions comparable levels of internalized ligand were microscopy. CHC-siRNA abrogated Met endocytosis in
detected in HeLa cells treated with 10 nM Alexa488-labeled LRR response to InlB and its derivative LRR but did not affect recepor 2 nM Alexa488-labeled InlB, whereas decreased ligand levels tor internalization in cells transfected with control siRNA.
were detected in cells treated with 2 nM Alexa488-labeled LRR. Uptake of the fluid phase marker Alexa594-labeled dextran
As expected, negligible internalized ligand was detected in cells 10,000 was unaffected (supplemental Fig. S3), whereas Alexatreated with Alexa488-labeled LRR-C242A. Thus, InlB and LRR Tfn internalization was reduced under these conditions (Fig.
are equally effective at triggering Met endocytosis under con- 4A). Collectively, these findings are consistent with a specific
ditions that induce comparable Met phosphorylation. Using block in clathrin-mediated endocytosis. Similarly, siRNA-meestablished populations of cell lines immortalized from the kid- diated depletion of Grb2 blocked Met uptake in response to
neys of Met null (⫺/⫺) mice that stably express comparable LRR and InlB. The requirement for Grb2 was specific for Met
levels of wild-type Met (WT-Met) or the kinase-deficient endocytosis, as clathrin-mediated uptake of Alexa-Tfn was
mutant K1110A (KinD-Met), we confirmed that Met kinase unaffected under these conditions (Fig. 4B). Thus, like InlB,
activity is required for receptor uptake in response to LRR. The LRR triggers Met internalization through clathrin-coated
cells were incubated in media containing InlB or LRR at 37 °C pits in a Grb2-dependent manner.
for increasing times, and the relative amount of internalized
Internalized Met Recycles in Response to LRR—Our data indiWT-Met versus KinD-Met was examined using the surface cate no difference in the internalization properties of Met in
JANUARY 9, 2009 • VOLUME 284 • NUMBER 2
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response to InlB or LRR, suggesting that post-endocytic mechanisms contribute to the prolonged stability and signaling of
Met in response to LRR. After InlB-induced Met internalization
into early endosomes, the receptor is normally sorted for degradation in the lysosome (18). The delay in Met degradation we
observed after treatment with the LRR fragment could be the
result of a slower rate of transit through early endosomes
and/or enhanced receptor recycling to the cell surface. Therefore, we used confocal microscopy to examine the distribution
of internalized Met. Alexa-LRR and Alexa-InlB were employed
as indicators for receptor co-localization with endogenous
EEA1 and CD63, specific markers for early endosomes and
multivesicular bodies (MVB), respectively (44, 45). HeLa cells
were allowed to internalize Alexa-LRR or Alexa-InlB into early
endosomes at 37 °C for 15 min. After internalization, the cells
were washed and then chased at 37 °C for 0, 30, or 60 min in
media lacking ligand to promote Met trafficking from early
endosomes. The cells were then fixed and co-stained for endogenous EEA1 or CD63 and examined using confocal microscopy
(supplemental Fig. S4). Increased chase times resulted in
decreased Alexa-InlB co-localization with EEA1 with a concomitant increase in ligand co-staining with CD63, consistent
with Met trafficking from early endosomes to MVBs (Fig. 5A).
The lower levels of Alexa-InlB that co-localized with CD63 at
60 min (49%) may be the result of InlB-Met complex dissociation or lysosomal degradation under these chase conditions. In
contrast to Alexa-InlB-treated cells, high levels of Alexa-LRR
co-localized with EEA1 at the 30- and 60-min chase times (Fig.
5B). The decreased extent of Alexa-LRR co-localization with
CD63 at 30 min is consistent with a delay in Met trafficking
from early endosomes to MVBs.
To further examine the fate of InlB- versus LRR-activated
Met, we developed a flow cytometry assay to quantify the recovery of internalized Met in the plasma membrane due to receptor recycling. Cycloheximide-treated HeLa cells were incubated in media lacking or containing ligand (2 nM InlB or 10 nM
LRR) for 15 min at 37 °C to promote Met internalization into
early endosomes. The cells were shifted to 4 °C to halt receptor
trafficking and then incubated with ice-cold 0.25% trypsin to
remove residual surface-associated receptor. After trypsin
inactivation, the cells were shifted to 37 °C in the presence of
cycloheximide for increasing times to promote receptor trafficking. Flow cytometry was used to examine the reappearance
of internalized receptor on the cell surface using an antibody
specific for the ectodomain of Met. Under these conditions
receptor recycling was undetectable in cells treated with InlB or
untreated control cells (Fig. 6), consistent with a previous study
showing that InlB treatment results in the lysosomal degradation of Met (18). Conversely, increasing levels of surface Met
were readily detected in LRR-treated cells during the chase conditions, consistent with the recycling of internalized Met back
to the plasma membrane. These results suggest that receptor
recycling to the cell surface is likely one of the causes of
increased Met stability in response to LRR.
Cell Motility Increases in Response to LRR—Our observation
that Met signaling in response to 10 nM LRR is sustained (refer
to Fig. 1B) suggested that LRR might promote cellular
responses resulting from Met signaling such as cell motility
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FIGURE 5. Met transit from early endosomes to the MVB is delayed in
response to LRR. HeLa cells were allowed to internalize Alexa488-labeled InlB
or LRR for 15 min at 37 °C and then chased at 37 °C in the absence of ligand for
increasing times to promote ligand transport from early endosomes to the
MVB. Cells were fixed and stained for endogenous EEA1 or CD63, and the
relative amount of internalized ligand that co-localizes with these proteins
was quantified using confocal microscopy. Values are expressed as the percentage of co-localization ⫾ S.E. normalized to an area from three independent experiments (*, p ⬍ 0.01, ANOVA).

and/or branching morphogenesis. MDCK cells are an epithelial
cell line that readily undergoes colony dispersal, increased cell
motility, and branching morphogenesis in response to Met signaling (8, 46, 47). Thus, we tested the ability of MDCK cells to
form tubules in semisolid collagen in response to InlB or LRR.
As shown in supplemental Fig. S5, MDCK cells grown in threedimensional collagen gels form simple cystic structures in the
absence of ligand. Treatment of the control cysts with HGF for
7 days induced marked branching tubulogenesis into the surrounding gel. Similarly, treatment for 7 days with InlB or LRR
resulted in the formation of long, thick tubules that were indistinguishable from those induced by HGF.
We next examined MDCK cell motility in response to various Met ligands. Serum-starved MDCK cells were incubated in
media without ligand or containing HGF, InlB, wild type, or
mutant LRR for 8 h, and the scattering response was examined
using phase contrast microscopy. Under these conditions, HGF
and InlB were indistinguishable in their ability to induce cell
scattering. Conversely, LRR treatment stimulated MDCK scattering in a dose-dependent manner (Fig. 7A). No scattering was
VOLUME 284 • NUMBER 2 • JANUARY 9, 2009
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FIGURE 6. Internalized Met recycles in response to LRR. Cycloheximidetreated HeLa cells were incubated in media lacking (Con) or containing ligand
(2 nM InlB or 10 nM LRR) for 15 min at 37 °C to internalize Met. The cells were
shifted to 4 °C, incubated in ice-cold trypsin to digest residual surface receptor, and then shifted to 37 °C in cycloheximide-containing media as indicated.
Recycled receptor was labeled with anti-Met antibody and quantified by flow
cytometry. Results represented the mean fluorescent intensities normalized
to control cells under each experimental condition from triplicate experiments. Bars represent the means for data across all experiments with S.E. (*,
p ⬍ 0.01, ANOVA).

observed in the absence of ligand or after treatment with the
inactive LRR mutant C242A.
We quantified the effect of LRR and InlB on MDCK motility
using scratch assays. In these studies cells were grown to confluency and serum-starved for 48 h in media containing 0.1%
sera to ensure that cell migration rather than cell growth was
measured. Linear scratches were induced using a pipette tip,
and the width of the wound was measured in pixels. The cells
were then incubated in medium with 0.2% serum without or
with 2 nM InlB or 10 nM LRR for up to 6 h, at which time the
width of the denuded area was measured. As shown in Fig. 7, B
and C, cell motility increased in response to InlB and, to a
greater extent LRR, relative to control cells incubated in media
lacking ligand. The wound width was reduced to 45.99 ⫾ 1.7
and 28.56 ⫾ 1.5% that of the original size in response to InlB and
LRR respectively (Fig. 7). In control cells the wound decreased
to 92.7 ⫾ 2.25% that of its original width at 6 h. To confirm that
the increase in cell motility induced by LRR was not cell typespecific, we performed scratch assays using HeLa cells. As
shown in supplemental Fig. S6, HeLa cell motility in response to
LRR was higher than that induced by full-length InlB, consistent with our motility studies using MDCK cells. Thus,
increased Met stability in response to LRR correlates with
increased motility of HeLa and MDCK cells.

DISCUSSION
Here we performed a structure/function analysis of the Listeria protein InlB. A key finding from our studies is that InlB
and its N-terminal LRR fragment differentially regulate the
endocytic trafficking of Met. Notably, our results indicate that
in contrast to InlB, LRR attenuates Met degradation and prolongs Met phosphorylation, correlating with increased cell
motility. The effect of LRR on Met degradation is specific as
InlB and LRR induce comparable rates of clathrin-mediated
Met internalization. Moreover, Met recycles back to the cell
JANUARY 9, 2009 • VOLUME 284 • NUMBER 2

surface in response to LRR but not InlB. These results suggest
that alterations in Met degradation contribute at least in part to
differences in the potencies of InlB and LRR with respect to
receptor signaling.
How do InlB and LRR differ in their efficiency in inducing
Met degradation? One possible explanation is related to the
relative binding affinity of InlB versus LRR for Met. In the case
of the EGF receptor, EGF but not transforming growth factor-␣
induces efficient receptor degradation. EGF remains tightly
associated with the EGF receptor after receptor internalization,
whereas transforming growth factor-␣ rapidly dissociates from
the receptor within the acidic environment of early endosomes,
resulting in receptor recycling to the cell surface (48). Our studies show a requirement for higher concentrations of LRR compared with InlB to achieve comparable levels of Met autophosphorylation. These findings suggest that differences in the
binding affinities of InlB and LRR for Met likely exist. However,
LRR appears to remain associated with Met during transit
through early endosomes and MVBs. Like Alexa-InlB, internalized Alexa-LRR is readily detected in EEA1- and CD63-positive
endocytic compartments. Although we cannot exclude the possibility that ligand affinity for Met is altered during transit
through endocytic compartments, our studies support the conclusion that binding of LRR or InlB is not adversely disrupted by
early endosomal pH.
An alternative explanation involves the different quaternary
states of InlB and LRR. Receptor dimerization is the proposed
mechanism for Met activation, as bivalent antibodies directed
against the ectodomain of Met induce receptor phosphorylation and trigger several downstream biological responses,
including cell motility, proliferation, invasion, tubulogenesis,
and angiogenesis (49). InlB is a monomeric protein and could
activate Met through a mechanism similar to that observed
with EGF. EGF induces a conformational change in its receptor,
resulting in the unmasking of a cryptic dimerization motif in
the receptor extracellular domain (for review, see Refs. 50 and
51). In this way binding of EGF converts the EGF receptor from
a dimerization-inhibited state to a dimerization-competent
state. The key to this transition involves the initial formation of
an asymmetric EGF-EGF receptor dimer (52), in which one of
the EGF-bound monomers relieves autoinhibition from the
other receptor monomer resulting in an active conformation.
By analogy, InlB binding to Met might induce a conformational
change that promotes receptor dimerization and, hence, receptor activation. In contrast to InlB, LRR is a dimer in solution.
Therefore, LRR may activate Met simply by clustering or crosslinking two receptors. This would suggest that additional
regions absent from LRR (e.g. inter-repeat or GW domains)
could be required to induce a conformational change sufficient
for maximal Met activation.
A recent model described by Niemann et al. (14) may provide
an alternative explanation for the different agonist properties of
full-length InlB and its LRR fragment. Although InlB is a monomer in solution, the authors propose that soluble InlB might
be clustered and form multimers upon interacting with heparan sulfate proteoglycans on the surface of host cells via the GW
domains of InlB. In this model InlB and LRR each act as multimers capable of clustering Met. The structural data of
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ization per se but is needed for efficient receptor down-regulation (19,
28). Consistent with these findings, a
somatic intronic mutation identified
in lung cancer results in a Met receptor mutant that shows decreased Cbl
binding, increased Met stability, and
tumorigenesis (58). Similarly, an artificial mutation introduced into the
juxtamembrane region of Met
(Y1003F) which inhibits recruitment of Cbl increases Met stability
and promotes cell proliferation in
response to HGF (28). However, it is
unclear from these studies whether
the respective Met mutants recycle
to the cell surface or remain on
intracellular membranes. In our
hands internalized Met does not
normally recycle back to the cell
surface in response to HGF.3
Although the mechanistic basis of
LRR- versus InlB-induced changes
in Met trafficking remain unclear, it
is tempting to speculate that Cbl
activation and binding or Cbl-mediated ubiquitination of Met may be
attenuated in LRR-treated cells,
leading to receptor recycling and,
hence, increased Met stability and sigFIGURE 7. LRR promotes cell motility. A, colonies of serum-starved MDCK cells were incubated for 8 h in
medium lacking ligand (Con) or supplemented with HGF (2 nM), InlB (2 nM), LRR (2 nM or 10 nM), or the mutant naling. Consistent with this scenario,
LRR-C242A (2 nM), and the scattering response was examined by phase-contrast microscopy. Bar, 20 m. The LRR treatment promotes motility of
results are representative of three independent experiments. B, confluent monolayers of serum-starved MDCK
were wounded with a pipette tip (n ⫽ 3/well) and immediately incubated in media without (Con) or with ligand MDCK and HeLa. Because lysosomal
(2 nM InlB, 10 nM LRR). The cells were imaged at identical points along the wound at 0 h or after incubation at sorting is a saturable process (59),
37 °C for 6 h. Representative images from three independent experiments are shown. C, the relative wound gap additional factors downstream of Cbl
was measured in pixels using Metamorph software, and the data are normalized to control cells. Bars represent
the mean ⫾ S.E. Significant differences between LRR- and InlB-treated cells with control cells were detected (*, may also be rate-limiting for Met degp ⬍ 0.01, ANOVA) and between LRR and InlB-treated cells (**, p ⬍ 0.01, ANOVA).
radation in LRR-treated cells.
In conclusion, we report the first
Niemann et al. (14) suggests that the binding of InlB to Met evidence that Met alters its trafficking pattern in response to a
induces a change in the orientation of the sema and Ig1 domains in truncated derivative of InlB, the LRR fragment. Altered Met
Met. The authors propose that the inter-repeat region in InlB is trafficking results in increased receptor stability and recycling
needed for this re-orientation, which they refer to as “clamping.” to the cell surface, correlating with prolonged Met signaling
According to this model, the LRR fragment can bind and cluster and cell motility. These studies support the contention that
Met but cannot induce the structural change. Perhaps the inability alterations in Met endocytic trafficking can augment receptor
of the LRR fragment to clamp the receptor-ligand complex results signaling and, hence, cellular responses. Additional studies will
in an activated receptor with altered signaling activity compared be required to determine how InlB and its fragment LRR alter
the ability of kinase-active Met to interact with critical compowith the situation obtained with InlB binding.
Conformational changes induced by the binding of InlB ver- nents of the endocytic machinery important for receptor sortsus LRR likely alter the ability of kinase-active Met to engage ing and degradation.
components of the endocytic machinery and/or attenuate
downstream signaling molecules important for receptor degra- Acknowledgments—We thank members of the Elferink laboratory for
dation. Recent studies suggest a strong correlation between helpful comments.
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